Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

Inclusion Criteria

• •Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
• •1. Patients who provide written informed consent to participate in the study
• •2. Male and female patients with ≥18 years of age
• •3. Diagnosis of clinically unequivocal moderate to severe HS
• •4. Patients for whom a therapy with secukinumab is medically indicated
• •5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
• •6. Treatment with secukinumab according to the latest version of SmPC
• •7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit